Prelude Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Prelude Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122K	Sell	11,300 -34,770	-75%	-$315K	0.01%	1083
2026 Q1	$584K	Buy	+46,070	New	+$523K	0.04%	452
2025 Q4	–	Sell	-33,037	Closed	-$396K	–	1485
2025 Q3	$396K	Buy	+33,037	New	+$348K	0.03%	588
2023 Q1	–	Sell	-15,353	Closed	-$90.4K	–	1383
2022 Q4	$90.4K	Buy	15,353 +143	+0.9%	+$483	﹤0.01%	1088
2022 Q3	$49K	Sell	15,210 -1,090	-7%	-$4.36K	﹤0.01%	1232
2022 Q2	$73K	Buy	+16,300	New	+$65K	﹤0.01%	1456

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prelude Capital Management's ORIC Position: Q2 2026 in Review

Prelude Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 75% in Q2 2026, selling an estimated $315K and leaving 11,300 shares worth $122K. The position accounts for 0.01% of the portfolio, ranked #1083.

Prelude Capital Management first reported a position in ORIC in Q2 2022 and has held it in 6 quarters since. The position peaked at $584K in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Prelude Capital Management held 11,300 shares of Oric Pharmaceuticals worth $122K as of Q2 2026.
Prelude Capital Management sold 34,770 Oric Pharmaceuticals shares in Q2 2026, an estimated $315K.
Oric Pharmaceuticals made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1083 holding.
Prelude Capital Management first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
Prelude Capital Management's Oric Pharmaceuticals position peaked at $584K in Q1 2026.
180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.